These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 6297382)
1. Synergism among BIOLF-62, phosphonoformate, and other antiherpetic compounds. Smith KO; Galloway KS; Ogilvie KK; Cheriyan UO Antimicrob Agents Chemother; 1982 Dec; 22(6):1026-30. PubMed ID: 6297382 [TBL] [Abstract][Full Text] [Related]
2. Increased efficacy of ganciclovir in combination with foscarnet against cytomegalovirus and herpes simplex virus type 2 in vitro and in vivo. Freitas VR; Fraser-Smith EB; Matthews TR Antiviral Res; 1989 Nov; 12(4):205-12. PubMed ID: 2559657 [TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of human herpesvirus-6 by phosphonoformate. Streicher HZ; Hung CL; Ablashi DV; Hellman K; Saxinger C; Fullen J; Salahuddin SZ J Virol Methods; 1988 Sep; 21(1-4):301-4. PubMed ID: 2972736 [TBL] [Abstract][Full Text] [Related]
4. Herpes simplex type 1 defective interfering particles do not affect the antiviral activity of acyclovir, foscarnet and adenine arabinoside. Harmenberg JG; Svensson LT Acta Virol; 1988 Mar; 32(2):153-5. PubMed ID: 2899962 [TBL] [Abstract][Full Text] [Related]
5. Mode of action of phosphonoformate as an anti-herpes simplex virus agent. Cheng YC; Grill S; Derse D; Chen JY; Caradonna SJ; Connor K Biochim Biophys Acta; 1981 Jan; 652(1):90-8. PubMed ID: 6260189 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds. Alenius S Arch Virol; 1980; 65(2):149-56. PubMed ID: 6252867 [TBL] [Abstract][Full Text] [Related]
7. Increased efficacy of phosphonoformate and phosphonoacetate inhibition of herpes simplex virus type 2 replication by encapsulation in liposomes. Szoka FC; Chu CJ Antimicrob Agents Chemother; 1988 Jun; 32(6):858-64. PubMed ID: 2843083 [TBL] [Abstract][Full Text] [Related]
8. [Antiviral activity of phosphonoacetic acid, phosphonopropionic acid, and trisodium phosphonoformate hexahydrate against herpesvirus hominis type 1 and type 2 in vitro]. Thiel KD; Wutzler P; Sprössig M; Bertram D Pharmazie; 1982 Aug; 37(8):608. PubMed ID: 6292963 [No Abstract] [Full Text] [Related]
9. Mutually exclusive inhibition of herpesvirus DNA polymerase by aphidicolin, phosphonoformate, and acyclic nucleoside triphosphates. Frank KB; Cheng YC Antimicrob Agents Chemother; 1985 Apr; 27(4):445-8. PubMed ID: 2988429 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. Reefschläger J; Wutzler P; Thiel KD; Herrmann G Pharm Res; 1987 Jun; 4(3):200-6. PubMed ID: 2855541 [TBL] [Abstract][Full Text] [Related]
11. Sensitivity of HSV clinical isolates to foscarnet and in vitro dual combination of foscarnet and acyclovir. Al-Samarai A; Kinghorn G; Potter C Chemioterapia; 1987 Jun; 6(2 Suppl):665-6. PubMed ID: 2855616 [No Abstract] [Full Text] [Related]
12. Ocular herpes simplex virus infections: reduced sensitivity to acyclovir in primary disease. Charles SJ; Gray JJ Br J Ophthalmol; 1990 May; 74(5):286-8. PubMed ID: 2162190 [TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses. Ayisi NK; Gupta SV; Babiuk LA Antiviral Res; 1985 Feb; 5(1):13-27. PubMed ID: 2984988 [TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of foscarnet on herpesvirus multiplication in cell culture. Schnürer J; Oberg B Arch Virol; 1981; 68(3-4):203-9. PubMed ID: 6268019 [TBL] [Abstract][Full Text] [Related]
15. Different in vitro effects of dual combinations of anti-herpes simplex virus compounds. Schinazi RF; Nahmias AJ Am J Med; 1982 Jul; 73(1A):40-8. PubMed ID: 6285731 [TBL] [Abstract][Full Text] [Related]
16. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro. Eriksson BF; Schinazi RF Antimicrob Agents Chemother; 1989 May; 33(5):663-9. PubMed ID: 2546487 [TBL] [Abstract][Full Text] [Related]
17. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. Chatis PA; Miller CH; Schrager LE; Crumpacker CS N Engl J Med; 1989 Feb; 320(5):297-300. PubMed ID: 2536137 [No Abstract] [Full Text] [Related]
18. A new nucleoside analog, 9-[[2-hydroxy-1-(hydroxymethyl)ethoxyl]methyl]guanine, highly active in vitro against herpes simplex virus types 1 and 2. Smith KO; Galloway KS; Kennell WL; Ogilvie KK; Radatus BK Antimicrob Agents Chemother; 1982 Jul; 22(1):55-61. PubMed ID: 6289741 [TBL] [Abstract][Full Text] [Related]
19. Sensitivity of arabinosyladenine-resistant mutants of herpes simplex virus to other antiviral drugs and mapping of drug hypersensitivity mutations to the DNA polymerase locus. Coen DM; Fleming HE; Leslie LK; Retondo MJ J Virol; 1985 Feb; 53(2):477-88. PubMed ID: 2982032 [TBL] [Abstract][Full Text] [Related]
20. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease. Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]